Phase 3Active, not recruiting
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (RENEW 2)
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes
- Sponsor
- Novo Nordisk A/S (Industry)
- Enrolment
- 330 planned
- Conditions
- Overweight; Obesity; Type 2 Diabetes
- Interventions
- Cagrilintide; Placebo (matched to Cagrilintide)
- Ages
- adults, older adults
- Registry
- NCT07220759, CTIS2024-519531-41-00
Full record on ClinicalTrials.gov
From the registry
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
Primary outcomes
- Relative change in body weight
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered